BioNTech Bets Big on Oncology as $1 Billion Buyback and First FDA Filing Converge

The Mainz-based biotech firm finds itself in an unusual position: burning through cash on R&D while sitting on a €16.8 billion war chest. In the first quarter of 2026, BioNTech posted a net loss of €531.9 million on revenue of just €118.1 million, with research and development spending hitting €557 million as it pours money into immuno-oncology and ADC programs. Yet the company has enough liquidity to finance its pipeline for years, and management has already started deploying capital in a different way.

A $1 billion share buyback programme got underway after shareholder approval. The company can repurchase up to 24.9 million shares — equivalent to 10% of its share capital — through May 2027. The shares acquired will be used to meet ongoing business obligations, marking a clear attempt to put the cash pile to work more efficiently while the business transitions away from its Covid-19 windfall.

That transition is now approaching its most tangible milestone. BioNTech, together with partner DualityBio, plans to file a Biologics License Application with the US Food and Drug Administration in 2026 for Trastuzumab Pamirtecan (BNT323/DB-1303) in advanced endometrium cancer. The antibody-drug conjugate has already secured Fast Track and Breakthrough Therapy designations from the regulator. The submission rests on Phase 2 data from a cohort of 145 patients, which showed a confirmed objective response rate of 47.9% — climbing to 73.1% in those with the highest HER2 expression. Median progression-free survival stood at 8.1 months, and the response rate held at 49.3% even among patients who had previously received checkpoint inhibitors. Crucially, the drug demonstrated efficacy across all HER2 expression levels, offering a potential treatment option for patients with low expression (IHC 1+ and IHC 2+) where no HER2-directed therapy is currently approved. In China, DualityBio submitted an application in April 2026 that the NMPA has accepted for review.

Trastuzumab Pamirtecan is far from the only arrow in the quiver. At the 2026 ASCO annual meeting, BioNTech presented encouraging data on two other candidates. Pumitamig combined with chemotherapy showed consistent antitumour activity in first-line non-small cell lung cancer, marking the third global dataset to confirm this effect after studies in small cell lung cancer and triple-negative breast cancer. Gotistobart, meanwhile, demonstrated durable tumour activity in heavily pre-treated patients with platinum-resistant ovarian cancer, offering a potential chemotherapy-free option. The oncology pipeline now encompasses more than 25 Phase 2 and Phase 3 studies, including 13 pivotal trials.

Should investors sell immediately? Or is it worth buying BioNTech?

The financial picture reflects the deliberate choice to spend now for future returns. Full-year revenue is forecast between €2.0 billion and €2.3 billion, still largely tied to the declining Covid vaccine business. To preserve cash, BioNTech is closing production sites in Idar-Oberstein, Marburg, Tübingen and Singapore by the end of 2027, and is exploring partial or full sales of each facility. From 2029, these measures are expected to generate annual cost savings of roughly €500 million.

The stock market has yet to reward the strategy. At €76.45, the share price sits about 27.7% below its 52-week high of €105.80 and has fallen roughly 7% since the start of the year. Every major moving average — the 50-day, 100-day and 200-day — now trades well above the current level. The 200-day line, a key technical hurdle, stands near €85. Only a decisive move above that level would brighten the chart.

For BioNTech, the second half of 2026 represents a make-or-break window. The BLA filing for Trastuzumab Pamirtecan, along with multiple Phase 3 data readouts, will provide the clearest signals yet on whether the oncology pivot can justify the billions being spent. The buyback may offer near-term support, but the stock’s fate rests on regulatory and clinical outcomes.